{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:10:35Z","timestamp":1791821435453,"version":"4.3.4"},"reference-count":60,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The temporal trend in adverse events regarding stroke prevention for nonvalvular atrial fibrillation (NVAF) in the direct oral anticoagulant (DOAC) era was rarely investigated comprehensively, especially taking into account potential changes in patient characteristics and anticoagulation treatment.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate time trends in patient characteristics, anticoagulation treatment, and prognosis of patients with incident NVAF in the Netherlands.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study assessed patients with incident NVAF initially recognized within a hospitalization between 2014 and 2018, using data from Statistics Netherlands. Participants were followed-up for 1 year from the hospital admission at which the incident NVAF diagnosis was made or until death, whichever occurred first. Data were analyzed from January 15, 2021, to March 8, 2023.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Calendar year of the incident NVAF diagnosis, according to which the participants were categorized into 5 cohorts.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Outcomes of interest were baseline patient characteristics, anticoagulation treatment, and occurrence of ischemic stroke or major bleeding within the 1-year follow-up after incident NVAF.<\/jats:p><\/jats:sec>Results<\/jats:title>Between 2014 and 2018, 301\u202f301 patients (mean [SD] age, 74.2 [11.9] years; 169\u202f748 [56.3%] male patients) experienced incident NVAF in the Netherlands, each of whom was categorized into 1 of 5 cohorts by calendar year. Baseline patient characteristics were broadly the same between cohorts with a mean (SD) CHA2<\/jats:sub>DS2<\/jats:sub>-VASc (congestive heart failure, hypertension, age \u226575 years [doubled], diabetes, stroke [doubled], vascular disease, age 65 to 74 years, and sex category [female]) score of 2.9 (1.7). The median (IQR) proportion of days covered by OACs (ie, vitamin K antagonists or DOACs) within the 1-year follow-up increased from 56.99% (0%-86.30%) to 75.62% (0%-94.52%), and DOACs increased from 5102 patients (13.5%) to 32\u202f314 patients (72.0%) among those who received OACs, gradually replacing VKAs as the first choice of OACs. Over the course of the study, there were statistically significant decreases in the 1-year cumulative incidence of ischemic stroke (from 1.63% [95% CI, 1.52%-1.73%] to 1.39% [95% CI, 1.30%-1.48%) and major bleeding (from 2.50% [95% CI, 2.37%-2.63%] to 2.07% [95% CI, 1.96%-2.19%]), and the association was consistent after adjusting for baseline patient characteristics and excluding those with preexisting chronic anticoagulation.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This cohort study of patients with incident NVAF diagnosed between 2014 and 2018 in the Netherlands found similar baseline characteristics, increased OAC use with DOACs being favored over time, and improved 1-year prognosis. Comorbidity burden, potential underuse of anticoagulation medications, and specific subgroups of patients with NVAF remain directions for future investigations and further improvement.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.9973","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T15:45:25Z","timestamp":1682437525000},"page":"e239973","source":"Crossref","is-referenced-by-count":21,"title":["Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands"],"prefix":"10.1001","volume":"6","author":[{"given":"Qingui","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrthe M. A.","family":"Toorop","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens F.","family":"Tops","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem M.","family":"Lijfering","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands"},{"name":"The Knowledge Institute of the Federation of Medical Specialists, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne C.","family":"Cannegieter","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands"},{"name":"Department of Medicine, Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"issue":"8","key":"zoi230318r1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"issue":"9989","key":"zoi230318r2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study.","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"zoi230318r3","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","article-title":"Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes.","volume":"120","author":"Staerk","year":"2017","journal-title":"Circ Res"},{"issue":"10","key":"zoi230318r4","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1212\/WNL.28.10.973","article-title":"Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study.","volume":"28","author":"Wolf","year":"1978","journal-title":"Neurology"},{"issue":"11","key":"zoi230318r5","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.cjca.2018.08.026","article-title":"2018 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation.","volume":"34","author":"Andrade","year":"2018","journal-title":"Can J Cardiol"},{"issue":"2","key":"zoi230318r6","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons.","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"zoi230318r7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"24","key":"zoi230318r8","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.120.049768","article-title":"Stroke prevention in atrial fibrillation: looking forward.","volume":"142","author":"Katsanos","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"zoi230318r9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation.","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"10","key":"zoi230318r10","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1093\/europace\/euq350","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).","volume":"12","author":"Camm","year":"2010","journal-title":"Europace"},{"key":"zoi230318r11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ahj.2017.08.011","article-title":"International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.","volume":"194","author":"Steinberg","year":"2017","journal-title":"Am Heart J"},{"key":"zoi230318r12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12959-017-0156-y","article-title":"NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands.","volume":"16","author":"van den Heuvel","year":"2018","journal-title":"Thromb J"},{"issue":"12","key":"zoi230318r13","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/eurheartj\/ehw658","article-title":"Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark.","volume":"38","author":"Gadsb\u00f8ll","year":"2017","journal-title":"Eur Heart J"},{"issue":"12","key":"zoi230318r14","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi230318r15","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi230318r16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi230318r17","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation.","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi230318r18","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.1182\/blood-2007-11-123711","article-title":"Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based.","volume":"111","author":"Levi","year":"2008","journal-title":"Blood"},{"issue":"5","key":"zoi230318r19","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jacc.2019.12.007","article-title":"Do observational studies agree with randomized trials: evaluation of oral anticoagulants in atrial fibrillation.","volume":"75","author":"Siontis","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"zoi230318r20","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.733300","article-title":"Real-world data of anticoagulant treatment in non-valvular atrial fibrillation.","volume":"8","author":"Calderon","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"zoi230318r21","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"zoi230318r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100386","article-title":"Temporal trends and patterns in atrial fibrillation incidence: a population-based study of 3\u00b74 million individuals.","volume":"17","author":"Wu","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"3","key":"zoi230318r23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/heartjnl-2020-316624","article-title":"Prevalence and incidence rates of atrial fibrillation in Norway 2004-2014.","volume":"107","author":"Kjerpeseth","year":"2021","journal-title":"Heart"},{"key":"zoi230318r24","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2147\/CLEP.S374468","article-title":"Prevalence and incidence rates of atrial fibrillation in Denmark 2004-2018.","volume":"14","author":"Hegelund","year":"2022","journal-title":"Clin Epidemiol"},{"issue":"9","key":"zoi230318r25","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1007\/s00392-019-01437-7","article-title":"Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database.","volume":"108","author":"Hohnloser","year":"2019","journal-title":"Clin Res Cardiol"},{"issue":"9","key":"zoi230318r26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012023","article-title":"Changes in anticoagulant utilization among United States nursing home residents with atrial fibrillation from 2011 to 2016.","volume":"8","author":"Alcusky","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"zoi230318r27","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.amjmed.2015.05.044","article-title":"National trends in ambulatory oral anticoagulant use.","volume":"128","author":"Barnes","year":"2015","journal-title":"Am J Med"},{"issue":"3","key":"zoi230318r28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018180","article-title":"Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases.","volume":"8","author":"Huiart","year":"2018","journal-title":"BMJ Open"},{"issue":"4","key":"zoi230318r29","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/joa3.v37.4","article-title":"Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world.","volume":"37","author":"Koziel","year":"2021","journal-title":"J Arrhythm"},{"issue":"20","key":"zoi230318r30","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1016\/j.jacc.2017.03.540","article-title":"Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation.","volume":"69","author":"Marzec","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"zoi230318r31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/heartjnl-2020-317006","article-title":"Clinical and budget impacts of changes in oral anticoagulation prescribing for atrial fibrillation.","volume":"107","author":"Orlowski","year":"2021","journal-title":"Heart"},{"issue":"7","key":"zoi230318r32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/heartjnl-2021-319338","article-title":"Trends in the pharmacological management of atrial fibrillation in UK general practice 2008-2018.","volume":"108","author":"Phillips","year":"2022","journal-title":"Heart"},{"issue":"11","key":"zoi230318r33","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007129","article-title":"Temporal trends in the use and comparative effectiveness of direct oral anticoagulant agents versus warfarin for nonvalvular atrial fibrillation: a Canadian population-based study.","volume":"6","author":"Yu","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"zoi230318r34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1136\/heartjnl-2016-309832","article-title":"Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.","volume":"103","author":"Camm","year":"2017","journal-title":"Heart"},{"key":"zoi230318r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100470","article-title":"Epidemiology, management, and outcomes of atrial fibrillation among 30 million citizens in Shanghai, China from 2015 to 2020: a medical insurance database study.","volume":"23","author":"Chen","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"zoi230318r36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2217\/fca-2020-0014","article-title":"GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke.","volume":"17","author":"Bassand","year":"2021","journal-title":"Future Cardiol"},{"issue":"10","key":"zoi230318r37","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s12471-022-01667-x","article-title":"Atrial fibrillation: trends in prevalence and antithrombotic prescriptions in the community.","volume":"30","author":"Joosten","year":"2022","journal-title":"Neth Heart J"},{"issue":"2","key":"zoi230318r38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/ndt\/gfy031","article-title":"A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.","volume":"34","author":"Feldberg","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"zoi230318r39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.007230","article-title":"Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation.","volume":"14","author":"Jackevicius","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"zoi230318r40","doi-asserted-by":"publisher","first-page":"910","DOI":"10.7326\/M20-6194","article-title":"Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation: a population-based cohort study.","volume":"174","author":"Dawwas","year":"2021","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi230318r41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jjcc.2017.08.005","article-title":"Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: analysis of the Shikoku Rivaroxaban Registry Trial (SRRT).","volume":"71","author":"Bando","year":"2018","journal-title":"J Cardiol"},{"issue":"1","key":"zoi230318r42","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/bcp.v88.1","article-title":"The association between increasing oral anticoagulant prescribing and atrial fibrillation related stroke in Ireland.","volume":"88","author":"Kennedy","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"17","key":"zoi230318r43","doi-asserted-by":"publisher","first-page":"e2343","DOI":"10.1212\/WNL.0000000000010647","article-title":"Time trends in incidence, comorbidity, and mortality of ischemic stroke in Denmark (1996-2016).","volume":"95","author":"Yafasova","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"zoi230318r44","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1177\/1747493019881349","article-title":"National trends in hospital admission, case fatality, and sex differences in atrial fibrillation-related strokes.","volume":"15","author":"Jewett","year":"2020","journal-title":"Int J Stroke"},{"issue":"5","key":"zoi230318r45","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.carrev.2018.07.019","article-title":"Trends in atrial fibrillation and prescription of oral anticoagulants and embolic strokes in Germany.","volume":"20","author":"Guelker","year":"2019","journal-title":"Cardiovasc Revasc Med"},{"issue":"3-6","key":"zoi230318r46","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000504082","article-title":"Secular trends of stroke epidemiology in \u00d6rebro, Sweden, 2017 compared to the trends in 1999: a population-based study.","volume":"48","author":"Appelros","year":"2019","journal-title":"Cerebrovasc Dis"},{"issue":"12","key":"zoi230318r47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209198","article-title":"Atrial fibrillation in patients with first-ever stroke: incidence trends and antithrombotic therapy before the event.","volume":"13","author":"Jung","year":"2018","journal-title":"PLoS One"},{"issue":"32","key":"zoi230318r48","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1093\/eurheartj\/ehy411","article-title":"A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation.","volume":"39","author":"Cowan","year":"2018","journal-title":"Eur Heart J"},{"issue":"5","key":"zoi230318r49","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jacep.2018.02.021","article-title":"Burden of atrial fibrillation-associated ischemic stroke in the United States.","volume":"4","author":"Alkhouli","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"issue":"1","key":"zoi230318r50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/jnnp-2015-311947","article-title":"Recent time trends in incidence, outcome and premorbid treatment of atrial fibrillation-related stroke and other embolic vascular events: a population-based study.","volume":"88","author":"Yiin","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"zoi230318r51","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cjco.2021.01.003","article-title":"Surveillance for outcomes selected as atrial fibrillation quality indicators in Canada: 10-year trends in stroke, major bleeding, and heart failure.","volume":"3","author":"Wilton","year":"2021","journal-title":"CJC Open"},{"issue":"6","key":"zoi230318r52","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014108","article-title":"Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF Study.","volume":"9","author":"Sanghai","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"40","key":"zoi230318r53","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1093\/eurheartj\/ehab421","article-title":"Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch nationwide cohort study.","volume":"42","author":"Toorop","year":"2021","journal-title":"Eur Heart J"},{"issue":"23","key":"zoi230318r54","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1001\/jama.2021.21222","article-title":"Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation.","volume":"326","author":"Ray","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"zoi230318r55","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy.","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"zoi230318r56","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/europace\/eut001","article-title":"Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies.","volume":"15","author":"Roskell","year":"2013","journal-title":"Europace"},{"key":"zoi230318r57","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab724.0436","article-title":"Risk of ischemic stroke in patients with atrial fibrillation and concomitant hyperthyroidism: a nationwide cohort study.","volume":"42","author":"Zhang","year":"2021","journal-title":"Eur Heart J"},{"issue":"8","key":"zoi230318r58","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/europace\/euv404","article-title":"Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF.","volume":"18","author":"DeVore","year":"2016","journal-title":"Europace"},{"issue":"6","key":"zoi230318r59","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1002\/ehf2.v8.6","article-title":"Newly diagnosed atrial fibrillation and hospital utilization in heart failure: a nationwide cohort study.","volume":"8","author":"Vinter","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"1","key":"zoi230318r60","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12875-019-1064-y","article-title":"How do Dutch general practitioners detect and diagnose atrial fibrillation: results of an online case vignette study.","volume":"20","author":"Verbiest-van Gurp","year":"2019","journal-title":"BMC Fam Pract"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2804040\/chen_2023_oi_230318_1681410443.84606.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T15:45:28Z","timestamp":1682437528000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2804040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.9973","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]}}}